先健(01302.HK)料中績倍增 惟股價逼近上市高位遇阻倒跌6%失10天線
先健科技(01302.HK)料中績倍增至少賺2億人民幣,該股承昨天回升5.8%勢,今天高開進一步升6.4%至5.86元,未能突破今年1月所創上市高位5.98元,獲利盤涌現,股價掉頭跌破10天線(5.25元),最低見5.12元,現造5.17元,倒跌6.2%,成交增至6,607萬股,爲半年來最多。
先健昨天收市後發盈喜指,受惠於各業務分部銷售收入和毛利增加,推動整體毛利年增70%-75%,以及期內投資收益按年增約1,770萬元人民幣(下同)至2,770萬元,預計至6月止中期純利不少於2億元,按年增長100%-110%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.